Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy

Nightingale, James; Lum, Benedict; Ladwa, Rahul; Simpson, Fiona; Panizza, Benedict

doi:10.1016/j.bbcan.2021.188523

Cited by 34 publications

(43 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For locoregional recurrence, more aggressive treatments are recommended, such as surgery or radiotherapy. Therapy for widely metastatic ACC is more challenging and depends primarily on systemic treatment [ 6 ]. Standard chemotherapy is a widely accepted treatment for patients with symptomatic metastases or fast-growing disease.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, chemotherapy may not be a viable option for this case after the resistance to combined first-line chemotherapy. As for immunotherapy, it is not effective because of the low tumor immunogenicity and absent PD-L1 expression in ACC [ 6 ]. In terms of targeted therapy, many new drugs directed against novel therapeutic targets have been developed.…”

Section: Discussionmentioning

confidence: 99%

“…ACC has also been reported arising from other relatively few sites, including trachea [ 2 ], breast [ 3 ], lacrimal gland [ 4 ] or skin [ 5 ]. It occurs most often between the ages of 40 and 60 years with no specific hereditary or environmental risk factors [ 6 ]. Although ACC exhibits a relatively slow clinical course, its long-term prognosis is poor due to the high rates of local recurrence and distant metastasis [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…The most frequently metastatic sites mainly include lungs (70%), bones (6%) and liver (3%) [ 8 , 9 ]. Surgical resection followed by postoperative radiation is the recognized treatment of ACC cases [ 6 ]. Whereas, metastatic ACC is generally more aggressive and incurable due to the lack of effective systemic therapies.…”

Section: Introductionmentioning

confidence: 99%

“…Whereas, metastatic ACC is generally more aggressive and incurable due to the lack of effective systemic therapies. Chemotherapy and targeted therapies have proven poor response rate and survival benefit [ 6 , 10 ]. Recent studies suggest that the microtubule inhibitor eribulin [ 11 ] and antiangiogenic therapy [ 12 , 13 ] could control ACC to some extent.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

Zheng

Lin

et al. 2021

Anti-Cancer Drugs

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC) is a rare salivary glands tumor and often displays aggressive behavior with frequent relapse and metastasis. The terminal ACC lacks standard treatment guidelines and is always accompanied by poor prognosis. Here, we report a case of rare perianal ACC who received resection and palliative adjuvant radiation. Five years later, PET-computed tomography (CT) showed perianal recurrence and multiple pulmonary metastases. Combined chemotherapy with doxorubicin, carboplatin and cyclophosphamide was applied for two cycles but ineffective. Further next-generation sequencing analysis of perianal tissue demonstrated the v-myb avian myelobastosis viral oncogene homolog and nuclear factor I/B fusion gene and two novel BCL-6 corepressor (BCOR) mutations (p.F1106Tfs*5 and p.L1524Hfs*8). The therapy was switched to eribulin and anlotinib and has been performed for eight cycles. At recent follow-ups, MRI and CT examinations revealed the diminishing perianal and pulmonary lesions. This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

Zheng

Lin

et al. 2021

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

A Precise and Intelligent Nanomedicine for Salivary Adenoid Cystic Carcinoma Treatment by Combining Antivascular Photodynamic Therapy and Neuroinhibitory Chemotherapy

Chen,

Han,

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Salivary adenoid cystic carcinoma (SACC) is one of the most common salivary gland malignancies. Current clinical therapies have limitations and cannot efficiently prevent the SACC development and metastasis. Hematogenous and neural spread are the two major routes of SACC metastasis. In this study, a precise and intelligent nanomedicine, RCDT, is designed to combine antivascular photodynamic therapy and neuroinhibitory chemotherapy against SACC. A tumor vessel‐targeted and reactive oxygen species (ROS)‐responsive photosensitizer (RC) is synthesized by linking cRGD to chlorin e6 (Ce6) via a bridge between the poly(ethylene glycol) and diselenide bonds. A neural‐targeted and pH‐responsive cytotoxic prodrug (DT) is synthesized by conjugating doxorubicin (DOX) with Tet1, a neural‐targeting peptide, via an acidic‐cleavable hydrazone bond. RC and DT are assembled to form RCDT via hydrophobic interactions, thereby shielding Tet1. Under the guidance of cRGD and the photodynamic action of Ce6, RCDT can precisely disrupt the tumor vasculature and simultaneously disintegrate to expose Tet1 by rupturing the diselenide bond. Guided by Tet1, disintegrated RCDT can be specifically internalized into neurons and release DOX to exert neuroinhibitory effects by cleaving the hydrazone bond. Using these stepwise dual‐targeting and dual‐responsive strategies, RCDT can efficiently suppress the growth and metastasis of SACC.

show abstract

The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial‐to‐mesenchymal transition

et al. 2022

View full text Add to dashboard Cite

Background: Perineural invasion (PNI) is a typical pathological characteristic of salivary adenoid cystic carcinoma (SACC) and other neurotrophic cancers. The mechanism of the neural microenvironment controlling tumor progression during the PNI process is unclear. In the present study, we investigated the role and molecular mechanisms of nerve-derived neuropeptide galanin (GAL) and its receptor (GALR2) in the regulation of PNI in SACC. Methods: Immunohistochemistry staining and clinical association studies were performed to analyze the expression of GAL and GALR2 in SACC tissues and their clinical value. Dorsal root ganglion or SH-SY5Y cells were co-cultured with SACC cells in vitro to simulate the interactions between the neural microenvironment and tumor cells, and a series of assays including transcriptome sequencing, Western blot, and Transwell were performed to investigate the role and molecular mechanism of GAL and GALR2 in the regulation of SACC cells. Moreover, both the in vitro and in vivo PNI models were established to assess the potential PNI-specific therapeutic effects by blocking the GAL/GALR2 axis. Results: GAL and GALR2 were highly expressed in SACC tissues, and were associated with PNI and poor prognosis in SACC patients (p < 0.05). Nerve-derived GAL activated GALR2 expression in SACC cells and induced epithelial-tomesenchymal transition (EMT) in SACC cells. Adding human recombinant GAL to the co-culture system promoted the proliferation, migration, and invasion of SACC cells significantly, but inhibited the apoptosis of SACC cells. Adding M871, a specific antagonist of GALR2, significantly blocked the above effects (p < 0.05) and inhibited the PNI of SACC cells in vitro and in vivo (p < 0.05). Conclusions: This study demonstrated that nerve-derived GAL activated GALR2 expression, and promoted EMT in SACC cells, thereby enhancing the | 4497 WANG et al. How to cite this article: Wang J, Yang Z, Liu Y, et al. The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial-to-mesenchymal transition.

show abstract

Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy

Cited by 34 publications

References 159 publications

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

A Precise and Intelligent Nanomedicine for Salivary Adenoid Cystic Carcinoma Treatment by Combining Antivascular Photodynamic Therapy and Neuroinhibitory Chemotherapy

The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial‐to‐mesenchymal transition

Contact Info

Product

Resources

About